,94 The findings presented suggest that upregulation of ST6GAL1 in prostate cancer cells could promote CD206+ M2 macrophages which could contribute to the relative resistance of bone metastatic CRPC to immune checkpoint therapy. The gene discussed is ST6GAL1; the disease is prostate carcinoma.